晚期黑色素瘤患者程序性死亡受体-1阻断的获益与毒性因种族而异:一项国际多中心观察性研究
该国际多中心回顾性观察研究纳入1135例接受抗PD-1单药治疗的晚期黑色素瘤患者,比较不同种族间的疗效与毒性。在白种人与东亚/西班牙裔/非洲裔患者中,非肢端皮肤/原发不明亚型的客观缓解率分别为54%与20%,中位无进展生存期分别为14.2个月与5.4个月。肢端/黏膜/葡萄膜亚型中两种族组疗效相似。白种人胃肠道免疫相关不良事件发生率较高,而内分泌、肝脏及其他罕见类型较低。
要点
- 非肢端皮肤/原发不明黑色素瘤中,白种人客观缓解率54% vs 东亚/西班牙裔/非洲裔20%,中位无进展生存期14.2个月 vs 5.4个月。
- 肢端/黏膜/葡萄膜黑色素瘤中,白种人与东亚/西班牙裔/非洲裔患者的客观缓解率和无进展生存期相似。
- 白种人胃肠道免疫相关不良事件发生率较高,内分泌、肝脏及其他罕见类型较低;毒性差异需基于种族的监测策略。
核心结论
- 临床获益的种族差异具有黑色素瘤亚型特异性,东亚、西班牙裔和非洲裔非肢端皮肤/原发不明黑色素瘤患者的临床获益比既往认识的更差。
- 不同黑色素瘤亚型中观察到的毒性种族差异提示需要基于种族的免疫相关不良事件监测策略。
- 需要更多研究来阐明这些差异的分子和免疫学决定因素。
研究设计与样本
- 研究为国际多中心回顾性观察性研究,收集2009年至2019年间在美国、澳大利亚和中国的五家独立机构接受抗PD-1单药治疗的不可切除或晚期黑色素瘤患者的临床数据。
- 共纳入1135例患者,按种族(白种人 vs 东亚/西班牙裔/非洲裔)和黑色素瘤亚型(非肢端皮肤/原发不明 vs 肢端/黏膜/葡萄膜)进行比较。
主要发现
- 在非肢端皮肤/原发不明亚型中,白种人患者的客观缓解率为54%(95%CI 50-57%),东亚/西班牙裔/非洲裔患者为20%(95%CI 13-28%),调整后P<0.001。
- 在非肢端皮肤/原发不明亚型中,白种人患者的中位无进展生存期为14.2个月(95%CI 10.7-20.3),东亚/西班牙裔/非洲裔患者为5.4个月(95%CI 4.5-7.0),调整后P<0.001。
- 多因素分析调整年龄、性别、原发解剖部位、转移分期、基线乳酸脱氢酶水平、突变状态和既往全身治疗后,白种人种族与更高的客观缓解率独立相关(比值比4.10,95%CI 2.48-6.81;调整后P<0.001)。
- 多因素分析调整相同变量后,白种人种族与更长的无进展生存期独立相关(风险比0.58,95%CI 0.46-0.74;调整后P<0.001)。
- 在肢端/黏膜/葡萄膜黑色素瘤中,白种人与东亚/西班牙裔/非洲裔患者的客观缓解率和无进展生存期相似;完全缓解率和总生存率也观察到类似的亚型特异性种族差异。
临床怎么用
- 作者认为,不同黑色素瘤亚型中观察到的毒性种族差异提示需要基于种族的免疫相关不良事件监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as East Asian, Hispanic and African. OBJECTIVES: To determine the efficacy and toxicity of PD-1 monotherapy in different ethnic groups. METHODS: Clinical data for patients with unresectable or advanced melanoma treated with anti-PD-1 monotherapy between 2009 and 2019 were collected retrospectively from five independent institutions in the USA, Australia and China. Tumour response, survival and immune-related adverse events (irAEs) were compared by ethnicity (white vs. East Asian/Hispanic/African) across different melanoma subtypes: nonacral cutaneous (NAC)/unknown primary (UP) and acral/mucosal/uveal. RESULTS: In total, 1135 patients were included. White patients had significantly higher objective response rate (ORR) [54%, 95% confidence interval (CI) 50-57% vs. 20%, 95% CI 13-28%; adjusted P < 0·001] and longer progression-free survival (14·2 months, 95% CI 10·7-20·3 vs. 5·4 months, 95% CI 4·5-7·0; adjusted P < 0·001) than East Asian, Hispanic and African patients in the NAC and UP subtypes. White ethnicity remained independently associated with a higher ORR (odds ratio 4·10, 95% CI 2·48-6·81; adjusted P < 0·001) and longer PFS (hazard ratio 0·58, 95% CI 0·46-0·74; adjusted P < 0·001) in multivariate analyses after adjustment for age, sex, primary anatomical location, metastasis stage, baseline lactate dehydrogenase level, mutational status and prior systemic treatment. White and East Asian/Hispanic/African patients shared similar ORR and progression-free survival in acral/mucosal/uveal melanomas. Similar melanoma-subtype-specific ethnic discrepancies were observed in complete response rate and overall survival. White patients had higher rates of gastrointestinal irAEs but lower rates of endocrine, liver and other rare types of irAEs. These differences in irAEs by ethnicity were not attributable to varying melanoma subtypes. CONCLUSIONS: Ethnic discrepancy in clinical benefit is specific to melanoma subtype, and East Asian, Hispanic and African patients with NAC and UP melanomas have poorer clinical benefits than previously recognized. The ethnic discrepancy in toxicity observed across different melanoma subtypes warrants an ethnicity-based irAE surveillance strategy. More research is needed to elucidate the molecular and immunological determinants of these differences. What is already known about this topic? There is a great difference in response to immunotherapy between different subtypes of melanoma (cutaneous, mucosal, acral and uveal) in patients with advanced disease. What does this study add? Our data show for the first time that there are differences between different ethnic groups in terms of both response and toxicity to immunotherapy beyond the well-appreciated discrepancies due to melanoma subtype.
引用
- Bai X, Shoushtari AN, Betof Warner A, et al. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol. 2022. PMID: 35293617. doi:10.1111/bjd.21241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。